array(40) {
  [0]=>
  string(4) "8552"
  ["article_id"]=>
  string(4) "8552"
  [1]=>
  string(161) "Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol"
  ["article_title"]=>
  string(161) "Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol"
  [2]=>
  string(150) "TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that detailed Phase "
  ["short_description"]=>
  string(150) "TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that detailed Phase "
  [3]=>
  string(250) "TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that detailed Phase 3 results of evinacumab were presented today as a late-breaking presentation at the American..."
  ["description"]=>
  string(250) "TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that detailed Phase 3 results of evinacumab were presented today as a late-breaking presentation at the American..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/regeneron-announces-american-college-cardiology-presentation-positive-phase-3-evinacumab-results-18500.html?utm_source=ddc&utm_medium=rss&utm_campaign=Regeneron+Announces+American+College+of+Cardiology+Presentation+of+Positive+Phase+3+Evinacumab+Results+in+Patie"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/regeneron-announces-american-college-cardiology-presentation-positive-phase-3-evinacumab-results-18500.html?utm_source=ddc&utm_medium=rss&utm_campaign=Regeneron+Announces+American+College+of+Cardiology+Presentation+of+Positive+Phase+3+Evinacumab+Results+in+Patie"
  [15]=>
  string(19) "2020-03-30 09:03:22"
  ["add_date"]=>
  string(19) "2020-03-30 09:03:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8553"
  ["article_id"]=>
  string(4) "8553"
  [1]=>
  string(223) "Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use"
  ["article_title"]=>
  string(223) "Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use"
  [2]=>
  string(150) "NEW BRUNSWICK, N.J., March 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19"
  ["short_description"]=>
  string(150) "NEW BRUNSWICK, N.J., March 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19"
  [3]=>
  string(246) "NEW BRUNSWICK, N.J., March 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant..."
  ["description"]=>
  string(246) "NEW BRUNSWICK, N.J., March 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/johnson-johnson-announces-lead-vaccine-candidate-covid-19-landmark-new-partnership-u-s-department-18490.html?utm_source=ddc&utm_medium=rss&utm_campaign=Johnson+%26+Johnson+Announces+a+Lead+Vaccine+Candidate+for+COVID-19%3B+Landmark+New+Partnership+with+U.S.+Depa"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/johnson-johnson-announces-lead-vaccine-candidate-covid-19-landmark-new-partnership-u-s-department-18490.html?utm_source=ddc&utm_medium=rss&utm_campaign=Johnson+%26+Johnson+Announces+a+Lead+Vaccine+Candidate+for+COVID-19%3B+Landmark+New+Partnership+with+U.S.+Depa"
  [15]=>
  string(19) "2020-03-30 09:03:21"
  ["add_date"]=>
  string(19) "2020-03-30 09:03:21"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8539"
  ["article_id"]=>
  string(4) "8539"
  [1]=>
  string(92) "COVID-19 LATEST: Pharmacies warned not to 'normalise' lack of responsible pharmacist"
  ["article_title"]=>
  string(92) "COVID-19 LATEST: Pharmacies warned not to 'normalise' lack of responsible pharmacist"
  [2]=>
  string(109) "All the most important developments in the COVID-19 pandemic for pharmacists and their teams, as they happen."
  ["short_description"]=>
  string(109) "All the most important developments in the COVID-19 pandemic for pharmacists and their teams, as they happen."
  [3]=>
  string(109) "All the most important developments in the COVID-19 pandemic for pharmacists and their teams, as they happen."
  ["description"]=>
  string(109) "All the most important developments in the COVID-19 pandemic for pharmacists and their teams, as they happen."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(165) "https://www.pharmaceutical-journal.com/news-and-analysis/news-blog/covid-19-latest-pharmacies-warned-not-to-normalise-lack-of-responsible-pharmacist/20207843.article"
  ["blog_url"]=>
  string(165) "https://www.pharmaceutical-journal.com/news-and-analysis/news-blog/covid-19-latest-pharmacies-warned-not-to-normalise-lack-of-responsible-pharmacist/20207843.article"
  [15]=>
  string(19) "2020-03-30 08:01:00"
  ["add_date"]=>
  string(19) "2020-03-30 08:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:02"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:02"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8674"
  ["article_id"]=>
  string(4) "8674"
  [1]=>
  string(21) "COVID-19 News Central"
  ["article_title"]=>
  string(21) "COVID-19 News Central"
  [2]=>
  string(153) "&#nlMedical device companies play an essential role in combatting the novel coronavirus (COVID-19). To help, MD+DI is tracking developments in evolving r"
  ["short_description"]=>
  string(153) "&#nlMedical device companies play an essential role in combatting the novel coronavirus (COVID-19). To help, MD+DI is tracking developments in evolving r"
  [3]=>
  string(6409) "&#nl
Medical device companies play an essential role in combatting the novel coronavirus (COVID-19). To help, MD+DI is tracking developments in evolving regulator policies, support from medtech suppliers, and the progress being made in meeting urgent needs for medical supplies. Click on the links below for details, and monitor this page for updates.
&#nl
Regulations, Policies, and Government Response
A Comprehensive Guide to COVID-19 EUA Submissions
How CDRH Is Responding to COVID-19
Proposal to Postpone EU Medical Device Regulation Underway
FDA Warns Against Fraudulent COVID-19 Tests and Treatments
FDA Issues Emergency Guidance for Non-Invasive Remote Monitoring Devices
FDA Issues Enforcement Policy for Ventilators Amid Shortage Concerns
U.S. Government Issues RFI for Solutions to Combat Coronavirus (COVID-19)
FDA Gives EUA to CDC Coronavirus Detection Test
FDA Lays Out Plan for Coronavirus Medical Countermeasures
&#nl
Supplier Support
Supplier Stories for the Week of March 22: Web Industries, Smalley, Sensirion, Qosina, and Bindatex
Supplier Stories for the Week of March 15: Nelson Laboratories
Virtual Medical Device Meetings You Need to Know About: Nanofabrica
How 3D Printing Is Helping in the Fight Against Coronavirus
&#nl
Medtech’s Response
Thermo Fisher Granted CE Mark for COVID-19 Test
Astrotech Developing New Test for COVID-19
Masimo’s Latest Acquisition Could Help in the Fight Against COVID-19
Abbott Brings Home EUA for COVID-19 Test
Rapid Diagnostics Firm Secures Financing Amid Covid-19 Crisis
BD Ramps Up Production, Collaborates on New Diagnostic in Response to COVID-19
Can Remote Patient Monitoring Curb COVID-19?
Medical Equipment Manufacturer Increases Production to Meet Demand Driven by COVID-19 Pandemic
More Tests on the Way as Coronavirus Spreads
Researchers Discover Interesting Imaging Features for Coronavirus
Co-Diagnostics Grabs CE Mark for Coronavirus IVD
8 Ways the Medtech Industry is Responding to the Coronavirus
&#nl
Market Impact
Obalon Mulling Over Strategic Options Amid COVID-19 Crisis
How Is COVID-19 Impacting Organ Transplants?
Conformis Faced with Tough Decision to Furlough One-Third of Its Workforce
The Biggest Threat to Medical Device Revenue Growth During the Pandemic
FDA Suspends Inspections Outside of the US Due to Coronavirus Outbreak
Coronavirus Hits Big Medtech Where It Hurts Most – Revenue
&#nl
Other Innovations
Apple Jumps into COVID-19 Fight with New Screening Tool
Elon Musk Talks Ventilators with Medtronic
Virginia Boy 3D Prints Mask for Sick Uncle and Others
"
  ["description"]=>
  string(6409) "&#nl
Medical device companies play an essential role in combatting the novel coronavirus (COVID-19). To help, MD+DI is tracking developments in evolving regulator policies, support from medtech suppliers, and the progress being made in meeting urgent needs for medical supplies. Click on the links below for details, and monitor this page for updates.
&#nl
Regulations, Policies, and Government Response
A Comprehensive Guide to COVID-19 EUA Submissions
How CDRH Is Responding to COVID-19
Proposal to Postpone EU Medical Device Regulation Underway
FDA Warns Against Fraudulent COVID-19 Tests and Treatments
FDA Issues Emergency Guidance for Non-Invasive Remote Monitoring Devices
FDA Issues Enforcement Policy for Ventilators Amid Shortage Concerns
U.S. Government Issues RFI for Solutions to Combat Coronavirus (COVID-19)
FDA Gives EUA to CDC Coronavirus Detection Test
FDA Lays Out Plan for Coronavirus Medical Countermeasures
&#nl
Supplier Support
Supplier Stories for the Week of March 22: Web Industries, Smalley, Sensirion, Qosina, and Bindatex
Supplier Stories for the Week of March 15: Nelson Laboratories
Virtual Medical Device Meetings You Need to Know About: Nanofabrica
How 3D Printing Is Helping in the Fight Against Coronavirus
&#nl
Medtech’s Response
Thermo Fisher Granted CE Mark for COVID-19 Test
Astrotech Developing New Test for COVID-19
Masimo’s Latest Acquisition Could Help in the Fight Against COVID-19
Abbott Brings Home EUA for COVID-19 Test
Rapid Diagnostics Firm Secures Financing Amid Covid-19 Crisis
BD Ramps Up Production, Collaborates on New Diagnostic in Response to COVID-19
Can Remote Patient Monitoring Curb COVID-19?
Medical Equipment Manufacturer Increases Production to Meet Demand Driven by COVID-19 Pandemic
More Tests on the Way as Coronavirus Spreads
Researchers Discover Interesting Imaging Features for Coronavirus
Co-Diagnostics Grabs CE Mark for Coronavirus IVD
8 Ways the Medtech Industry is Responding to the Coronavirus
&#nl
Market Impact
Obalon Mulling Over Strategic Options Amid COVID-19 Crisis
How Is COVID-19 Impacting Organ Transplants?
Conformis Faced with Tough Decision to Furlough One-Third of Its Workforce
The Biggest Threat to Medical Device Revenue Growth During the Pandemic
FDA Suspends Inspections Outside of the US Due to Coronavirus Outbreak
Coronavirus Hits Big Medtech Where It Hurts Most – Revenue
&#nl
Other Innovations
Apple Jumps into COVID-19 Fight with New Screening Tool
Elon Musk Talks Ventilators with Medtronic
Virginia Boy 3D Prints Mask for Sick Uncle and Others
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(43) "https://www.mddionline.com/covid-19-central"
  ["blog_url"]=>
  string(43) "https://www.mddionline.com/covid-19-central"
  [15]=>
  string(19) "2020-03-28 16:08:37"
  ["add_date"]=>
  string(19) "2020-03-28 16:08:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:39"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8554"
  ["article_id"]=>
  string(4) "8554"
  [1]=>
  string(232) "Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies"
  ["article_title"]=>
  string(232) "Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies"
  [2]=>
  string(150) "KENILWORTH, N.J.--(BUSINESS WIRE) March 28, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentat"
  ["short_description"]=>
  string(150) "KENILWORTH, N.J.--(BUSINESS WIRE) March 28, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentat"
  [3]=>
  string(250) "KENILWORTH, N.J.--(BUSINESS WIRE) March 28, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its..."
  ["description"]=>
  string(250) "KENILWORTH, N.J.--(BUSINESS WIRE) March 28, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/investigational-vericiguat-significantly-reduced-risk-composite-endpoint-heart-failure-18503.html?utm_source=ddc&utm_medium=rss&utm_campaign=Investigational+Drug+Vericiguat+Significantly+Reduced+the+Risk+of+the+Composite+Endpoint+of+Heart+Failure+Hospitalization"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/investigational-vericiguat-significantly-reduced-risk-composite-endpoint-heart-failure-18503.html?utm_source=ddc&utm_medium=rss&utm_campaign=Investigational+Drug+Vericiguat+Significantly+Reduced+the+Risk+of+the+Composite+Endpoint+of+Heart+Failure+Hospitalization"
  [15]=>
  string(19) "2020-03-28 10:03:59"
  ["add_date"]=>
  string(19) "2020-03-28 10:03:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8555"
  ["article_id"]=>
  string(4) "8555"
  [1]=>
  string(158) "Novartis New Analysis Further Shows Durable and Potent LDL-C Reduction with Inclisiran, an Investigational First-in-Class siRNA Cholesterol-Lowering Treatment"
  ["article_title"]=>
  string(158) "Novartis New Analysis Further Shows Durable and Potent LDL-C Reduction with Inclisiran, an Investigational First-in-Class siRNA Cholesterol-Lowering Treatment"
  [2]=>
  string(150) "East Hanover, N.J., March 28, 2020 — Novartis today announced results from a prespecified analysis of pooled data from three Phase III stud"
  ["short_description"]=>
  string(150) "East Hanover, N.J., March 28, 2020 — Novartis today announced results from a prespecified analysis of pooled data from three Phase III stud"
  [3]=>
  string(251) "East Hanover, N.J., March 28, 2020 — Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment..."
  ["description"]=>
  string(251) "East Hanover, N.J., March 28, 2020 — Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/novartis-new-analysis-further-shows-durable-potent-ldl-c-reduction-inclisiran-investigational-first-18495.html?utm_source=ddc&utm_medium=rss&utm_campaign=Novartis+New+Analysis+Further+Shows+Durable+and+Potent+LDL-C+Reduction+with+Inclisiran%2C+an+Investigational"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/novartis-new-analysis-further-shows-durable-potent-ldl-c-reduction-inclisiran-investigational-first-18495.html?utm_source=ddc&utm_medium=rss&utm_campaign=Novartis+New+Analysis+Further+Shows+Durable+and+Potent+LDL-C+Reduction+with+Inclisiran%2C+an+Investigational"
  [15]=>
  string(19) "2020-03-28 09:03:26"
  ["add_date"]=>
  string(19) "2020-03-28 09:03:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8661"
  ["article_id"]=>
  string(4) "8661"
  [1]=>
  string(68) "Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance"
  ["article_title"]=>
  string(68) "Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance"
  [2]=>
  string(150) "Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coa"
  ["short_description"]=>
  string(150) "Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coa"
  [3]=>
  string(376) "Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one. Sanofi (NYSE: SNY) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: TBIO), […]"
  ["description"]=>
  string(376) "Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one. Sanofi (NYSE: SNY) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: TBIO), […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(107) "https://xconomy.com/europe/2020/03/27/sanofi-adds-mrna-covid-19-vaccine-bet-through-translate-bio-alliance/"
  ["blog_url"]=>
  string(107) "https://xconomy.com/europe/2020/03/27/sanofi-adds-mrna-covid-19-vaccine-bet-through-translate-bio-alliance/"
  [15]=>
  string(19) "2020-03-28 09:00:31"
  ["add_date"]=>
  string(19) "2020-03-28 09:00:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8582"
  ["article_id"]=>
  string(4) "8582"
  [1]=>
  string(56) "Mylan Waives U.S. Exclusivity for Possible COVID-19 Drug"
  ["article_title"]=>
  string(56) "Mylan Waives U.S. Exclusivity for Possible COVID-19 Drug"
  [2]=>
  string(158) "&#nl        Mylan said it will waive its exclusive U.S. distribution rights for its copycat of AbbVie’s HIV antiviral Kaletra (lopinavir/ritonavir) to "
  ["short_description"]=>
  string(158) "&#nl        Mylan said it will waive its exclusive U.S. distribution rights for its copycat of AbbVie’s HIV antiviral Kaletra (lopinavir/ritonavir) to "
  [3]=>
  string(238) "&#nl        Mylan said it will waive its exclusive U.S. distribution rights for its copycat of AbbVie’s HIV antiviral Kaletra (lopinavir/ritonavir) to allow other suppliers to manufacture the potential COVID-19 treatment.&#nl      "
  ["description"]=>
  string(238) "&#nl        Mylan said it will waive its exclusive U.S. distribution rights for its copycat of AbbVie’s HIV antiviral Kaletra (lopinavir/ritonavir) to allow other suppliers to manufacture the potential COVID-19 treatment.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(94) "https://www.fdanews.com/articles/196431-mylan-waives-us-exclusivity-for-possible-covid-19-drug"
  ["blog_url"]=>
  string(94) "https://www.fdanews.com/articles/196431-mylan-waives-us-exclusivity-for-possible-covid-19-drug"
  [15]=>
  string(19) "2020-03-28 07:19:14"
  ["add_date"]=>
  string(19) "2020-03-28 07:19:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:06"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8556"
  ["article_id"]=>
  string(4) "8556"
  [1]=>
  string(178) "Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation"
  ["article_title"]=>
  string(178) "Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation"
  [2]=>
  string(154) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  ["short_description"]=>
  string(154) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  [3]=>
  string(255) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  ["description"]=>
  string(255) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/leronlimab-seven-patients-severe-covid-19-demonstrated-promise-two-intubated-patients-icu-removed-18486.html?utm_source=ddc&utm_medium=rss&utm_campaign=Leronlimab+Used+in+Seven+Patients+with+Severe+COVID-19+Demonstrated+Promise+with+Two+Intubated+Patients+in+ICU"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/leronlimab-seven-patients-severe-covid-19-demonstrated-promise-two-intubated-patients-icu-removed-18486.html?utm_source=ddc&utm_medium=rss&utm_campaign=Leronlimab+Used+in+Seven+Patients+with+Severe+COVID-19+Demonstrated+Promise+with+Two+Intubated+Patients+in+ICU"
  [15]=>
  string(19) "2020-03-28 07:03:34"
  ["add_date"]=>
  string(19) "2020-03-28 07:03:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8557"
  ["article_id"]=>
  string(4) "8557"
  [1]=>
  string(270) "CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation"
  ["article_title"]=>
  string(270) "CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation"
  [2]=>
  string(154) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  ["short_description"]=>
  string(154) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  [3]=>
  string(255) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  ["description"]=>
  string(255) "VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/cytodyn-files-fda-suggested-modifications-ind-protocol-phase-2-clinical-trial-covid-19-patients-18487.html?utm_source=ddc&utm_medium=rss&utm_campaign=CytoDyn+Files+FDA-Suggested+Modifications+to+IND+and+Protocol+for+Phase+2+Clinical+Trial+for+COVID-19+Patients+w"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/cytodyn-files-fda-suggested-modifications-ind-protocol-phase-2-clinical-trial-covid-19-patients-18487.html?utm_source=ddc&utm_medium=rss&utm_campaign=CytoDyn+Files+FDA-Suggested+Modifications+to+IND+and+Protocol+for+Phase+2+Clinical+Trial+for+COVID-19+Patients+w"
  [15]=>
  string(19) "2020-03-28 07:03:10"
  ["add_date"]=>
  string(19) "2020-03-28 07:03:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8662"
  ["article_id"]=>
  string(4) "8662"
  [1]=>
  string(68) "Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others"
  ["article_title"]=>
  string(68) "Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others"
  [2]=>
  string(158) "Equillium has halted two clinical trials of its lead drug candidate out of an “abundance of caution” related to the coronavirus outbreak but conti"
  ["short_description"]=>
  string(158) "Equillium has halted two clinical trials of its lead drug candidate out of an “abundance of caution” related to the coronavirus outbreak but conti"
  [3]=>
  string(359) "Equillium has halted two clinical trials of its lead drug candidate out of an “abundance of caution” related to the coronavirus outbreak but continues to enroll in a third, which is evaluating the antibody as a treatment for acute graft-versus-host disease. The decision made by the San Diego biotech, revealed in its annual report filed […]"
  ["description"]=>
  string(359) "Equillium has halted two clinical trials of its lead drug candidate out of an “abundance of caution” related to the coronavirus outbreak but continues to enroll in a third, which is evaluating the antibody as a treatment for acute graft-versus-host disease. The decision made by the San Diego biotech, revealed in its annual report filed […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(109) "https://xconomy.com/san-diego/2020/03/27/equillium-continues-graft-versus-host-disease-trial-pauses-2-others/"
  ["blog_url"]=>
  string(109) "https://xconomy.com/san-diego/2020/03/27/equillium-continues-graft-versus-host-disease-trial-pauses-2-others/"
  [15]=>
  string(19) "2020-03-28 06:12:33"
  ["add_date"]=>
  string(19) "2020-03-28 06:12:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8530"
  ["article_id"]=>
  string(4) "8530"
  [1]=>
  string(173) "FDA Approves Triferic AVNU (ferric pyrophosphate citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients"
  ["article_title"]=>
  string(173) "FDA Approves Triferic AVNU (ferric pyrophosphate citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients"
  [2]=>
  string(150) "WIXOM, Mich., March 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the &ldqu"
  ["short_description"]=>
  string(150) "WIXOM, Mich., March 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the &ldqu"
  [3]=>
  string(247) "WIXOM, Mich., March 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and..."
  ["description"]=>
  string(247) "WIXOM, Mich., March 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-triferic-avnu-ferric-pyrophosphate-citrate-intravenous-formulation-triferic-5192.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Triferic+AVNU+%28ferric+pyrophosphate+citrate%29%2C+Intravenous+Formulation+of+Triferic+for+Replacement+of+Iron+an"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-triferic-avnu-ferric-pyrophosphate-citrate-intravenous-formulation-triferic-5192.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Triferic+AVNU+%28ferric+pyrophosphate+citrate%29%2C+Intravenous+Formulation+of+Triferic+for+Replacement+of+Iron+an"
  [15]=>
  string(19) "2020-03-28 06:03:26"
  ["add_date"]=>
  string(19) "2020-03-28 06:03:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:00"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}